Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Addiction ; 118(5): 857-869, 2023 05.
Artigo em Inglês | MEDLINE | ID: mdl-36459420

RESUMO

BACKGROUND AND AIMS: Individuals with opioid use disorder (OUD) suffer disproportionately from COVID-19. To inform clinical management of OUD patients, research is needed to identify characteristics associated with COVID-19 progression and death among this population. We aimed to investigate the role of OUD and specific comorbidities on COVID-19 progression among hospitalized OUD patients. DESIGN: Retrospective cohort study of merged electronic health records (EHR) from five large private health systems. SETTING: New York City, New York, USA, 2011-21. PARTICIPANTS: Adults with a COVID-19 encounter and OUD or opioid overdose diagnosis between March 2020 and February 2021. MEASUREMENTS: Primary exposure included diagnosis of OUD/opioid overdose. Risk factors included age, sex, race/ethnicity and common medical, substance use and psychiatric comorbidities known to be associated with COVID-19 severity. Outcomes included COVID-19 hospitalization and subsequent intubation, acute kidney failure, severe sepsis and death. FINDINGS: Of 110 917 COVID-19+ adults, 1.17% were ever diagnosed with OUD/opioid overdose. OUD patients had higher risk of COVID-19 hospitalization [adjusted risk ratio (aRR) = 1.40, 95% confidence interval (CI) = 1.33, 1.47], intubation [adjusted odds ratio (aOR) = 2.05, 95% CI = 1.74, 2.42], kidney failure (aRR = 1.51, 95% CI = 1.34, 1.70), sepsis (aRR = 2.30, 95% CI = 1.88, 2.81) and death (aRR = 2.10, 95% CI = 1.84, 2.40). Among hospitalized OUD patients, risks for worse COVID-19 outcomes included being male; older; of a race/ethnicity other than white, black or Hispanic; and having comorbid chronic kidney disease, diabetes, obesity or cancer. Protective factors included having asthma, hepatitis-C and chronic pain. CONCLUSIONS: Opioid use disorder patients appear to have a substantial risk for COVID-19-associated morbidity and mortality, with particular comorbidities and treatments moderating this risk.


Assuntos
COVID-19 , Overdose de Opiáceos , Transtornos Relacionados ao Uso de Opioides , Adulto , Humanos , Masculino , Feminino , COVID-19/epidemiologia , Estudos Retrospectivos , Overdose de Opiáceos/epidemiologia , Transtornos Relacionados ao Uso de Opioides/tratamento farmacológico , Hospitais , Cidade de Nova Iorque/epidemiologia
2.
Early Hum Dev ; 139: 104837, 2019 12.
Artigo em Inglês | MEDLINE | ID: mdl-31455569

RESUMO

INTRODUCTION: Congenital heart disease (CHD) is one of the most common causes of infant admission to pediatric intensive care and is associated with profound psychological stress for mothers, fathers and their infants. Intensive care unit admission represents an opportunity to offer evidence-based strategies to prevent or minimize severe psychological distress and promote secure bonding and attachment, alongside high-quality infant medical care. OBJECTIVES: We aimed to identify, synthesize and critically appraise published evidence on the efficacy and cost-effectiveness of mental health interventions delivered in neonatal, pediatric or cardiac intensive care units for parents of infants with CHD. A secondary goal was to develop recommendations for advancing health policy, practice and research in the field. METHODS: In accordance with a prospectively registered protocol (CRD42019114507), six electronic databases were systematically searched for studies reporting results of a controlled trial of a mental health intervention for parents of infants aged 0-12 months with a congenital anomaly requiring intensive care unit admission. To maximize generalizability of results, trials involving infants with any type of structural congenital anomaly requiring surgery were included. Outcomes included intervention type, process, efficacy, and cost-effectiveness. RESULTS: Across all forms of congenital anomaly, only five trials met inclusion criteria (four in CHD, one in gastrointestinal malformation). All interventions engaged parents face-to-face, but each had a distinct therapeutic approach (parent-infant interaction and bonding, early pediatric palliative care, psycho-education, parenting skills training, and family-centered nursing). Four of the five trials demonstrated efficacy in reducing maternal anxiety, although the quality of evidence was low. Positive results were also found for maternal coping, mother-infant attachment, parenting confidence and satisfaction with clinical care, as well as infant mental (but not psychomotor) development at 6 months. Mixed results were found for maternal depression and infant feeding. No evidence of efficacy was found for improving parent, infant or family quality of life, physical health or length of infant hospital stay, and there were no data on cost-effectiveness. CONCLUSIONS: Stronger evidence for the efficacy of mental health interventions to buffer the effects of intensive care unit admission for parents of infants with CHD is urgently needed. Robust, high-quality trials are lacking, despite the established need and demand, and health policies prioritizing parent mental health care in the context of early childhood adversity are needed.


Assuntos
Cardiopatias Congênitas , Serviços de Saúde Mental , Pais/psicologia , Estresse Psicológico , Ansiedade/terapia , Análise Custo-Benefício , Feminino , Cardiopatias Congênitas/terapia , Humanos , Lactente , Recém-Nascido , Unidades de Terapia Intensiva/economia , Masculino , Saúde Mental , Relações Pais-Filho
3.
Int J Qual Health Care ; 29(4): 548-556, 2017 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-28934402

RESUMO

OBJECTIVE: To assess the utility of the proposed World Health Organization (WHO)'s International Classification of Disease (ICD) framework for classifying patient safety events. SETTING: Independent classification of 45 clinical vignettes using a web-based platform. STUDY PARTICIPANTS: The WHO's multi-disciplinary Quality and Safety Topic Advisory Group. MAIN OUTCOME MEASURE(S): The framework consists of three concepts: harm, cause and mode. We defined a concept as 'classifiable' if more than half of the raters could assign an ICD-11 code for the case. We evaluated reasons why cases were nonclassifiable using a qualitative approach. RESULTS: Harm was classifiable in 31 of 45 cases (69%). Of these, only 20 could be classified according to cause and mode. Classifiable cases were those in which a clear cause and effect relationship existed (e.g. medication administration error). Nonclassifiable cases were those without clear causal attribution (e.g. pressure ulcer). Of the 14 cases in which harm was not evident (31%), only 5 could be classified according to cause and mode and represented potential adverse events. Overall, nine cases (20%) were nonclassifiable using the three-part patient safety framework and contained significant ambiguity in the relationship between healthcare outcome and putative cause. CONCLUSIONS: The proposed framework enabled classification of the majority of patient safety events. Cases in which potentially harmful events did not cause harm were not classifiable; additional code categories within the ICD-11 are one proposal to address this concern. Cases with ambiguity in cause and effect relationship between healthcare processes and outcomes remain difficult to classify.


Assuntos
Classificação Internacional de Doenças , Segurança do Paciente/normas , Organização Mundial da Saúde , Humanos , Erros Médicos/classificação , Indicadores de Qualidade em Assistência à Saúde
4.
Am J Manag Care ; 14(8): 497-504, 2008 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-18690765

RESUMO

OBJECTIVE: To determine optimal methods of identifying enrollees with possible depression for additional depression screening in the context of a care management program for chronically ill Medicare recipients. STUDY DESIGN: Observational analysis of telephone and mail survey and claims data collected for the Medicare Health Support (MHS) program. METHODS: This study examines data from 14,902 participants with diabetes mellitus and/or congestive heart failure in the MHS program administered by Green Ribbon Health, LLC. Depression screening was performed by administering a 2-item screen (the Patient Health Questionnaire 2 [PHQ-2]) by telephone or by mail. Additional information about possible depression was drawn from International Classification of Diseases, Ninth Revision (ICD-9) depression diagnoses on claims and from self-reported use of antidepressant medications. We evaluated positive depression screens using the PHQ-2 administered via telephone versus mail, examined variations in screener-positive findings by care manager, and compared rates of positive screens with antidepressant use and with claims diagnoses of depression. RESULTS: Almost 14% of participants received an ICD-9 diagnosis of depression during the year before program enrollment; 7.1% reported taking antidepressants, and 5.1% screened positive for depression on the PHQ-2. We found substantial variation in positive depression screens by care manager that could not be explained by case mix, prior depression diagnoses, or current depression treatment. After adjusting for demographic and clinical differences, the PHQ-2-positive screen rates were 6.5% by telephone and 14.1% by mail (P <.001). CONCLUSION: A multipronged effort composed of mail screening (using the PHQ-2), self-reported antidepressant use, and claims diagnoses of depression may capture the greatest number of enrollees with possible depression.


Assuntos
Transtorno Depressivo/diagnóstico , Gerenciamento Clínico , Programas de Rastreamento/métodos , Medicare Part D/estatística & dados numéricos , Idoso , Idoso de 80 Anos ou mais , Antidepressivos/economia , Antidepressivos/uso terapêutico , Doença Crônica , Comorbidade , Transtorno Depressivo/tratamento farmacológico , Transtorno Depressivo/epidemiologia , Complicações do Diabetes/economia , Complicações do Diabetes/psicologia , Planos de Pagamento por Serviço Prestado , Feminino , Florida , Pesquisas sobre Atenção à Saúde , Insuficiência Cardíaca/complicações , Insuficiência Cardíaca/economia , Insuficiência Cardíaca/psicologia , Humanos , Revisão da Utilização de Seguros , Masculino , Programas de Assistência Gerenciada , Programas de Rastreamento/economia , Cooperação do Paciente , Estados Unidos
5.
Psychiatr Serv ; 56(3): 283-91, 2005 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-15746502

RESUMO

OBJECTIVES: This study provided generalizable national data on the treatment of adult patients with schizophrenia in the United States and assessed conformance with the practice guideline treatment recommendations of the Schizophrenia Patient Outcomes Research Team and the American Psychiatric Association. METHODS: National data from the American Psychiatric Institute for Research and Education's 1999 Practice Research Network study of psychiatric patients and treatments were used to examine treatment patterns for 151 adult patients with schizophrenia. Analyses were performed and adjusted for the weights and sample design to generate nationally representative estimates. RESULTS: Findings indicated that patients with schizophrenia who were treated by psychiatrists had complex clinical problems and were markedly disabled. Forty-one percent of patients had a comorbid axis I disorder, and 75 percent were currently unemployed. Thirty-five percent were currently experiencing medication side effects, and 37 percent were currently experiencing problems with treatment adherence. Although most patients received guideline-consistent psychopharmacologic treatment, treatment was characterized by significant polypharmacy. Rates of conformance with the guideline recommendations were significantly lower for psychosocial recommendations than for psychopharmacologic recommendations. Although 69 percent of patients received at least some psychosocial treatment, none of the unemployed patients received vocational rehabilitation services in the past 30 days. CONCLUSIONS: These data suggest unmet need for psychosocial treatment services among individuals with schizophrenia. These findings raise questions about whether currently available antipsychotic medications are being used optimally or whether they offer limited effectiveness for patients with complex clinical problems who are treated in routine psychiatric practice.


Assuntos
Fidelidade a Diretrizes/estatística & dados numéricos , Serviços de Saúde Mental/normas , Padrões de Prática Médica/estatística & dados numéricos , Psiquiatria/normas , Esquizofrenia/terapia , Adolescente , Adulto , Idoso , Administração de Caso , Estudos Transversais , Demografia , Readaptação ao Emprego/estatística & dados numéricos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Guias de Prática Clínica como Assunto , Psiquiatria/métodos , Reabilitação Vocacional , Esquizofrenia/epidemiologia , Estados Unidos
6.
Am J Geriatr Psychiatry ; 13(3): 250-4, 2005 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-15728757

RESUMO

OBJECTIVE: The burden of medical comorbidities was compared between older (> or =60 years) and younger patients with serious mental illness. METHODS: Patients (N=8,083) diagnosed with schizophrenia, schizoaffective disorder, or bipolar disorder in 2001 were identified from VA facilities in the mid-Atlantic region. Medical comorbidities were identified by an ICD-9-based clinical classification algorithm. RESULTS: Older, versus younger, patients were more likely to be diagnosed with cardiovascular or pulmonary conditions, and less likely to be diagnosed with substance-use disorders or hepatic conditions. CONCLUSIONS: More aggressive detection and management of general-medical comorbidities in older patients with serious mental illness is paramount.


Assuntos
Transtorno Bipolar/epidemiologia , Transtornos Psicóticos/epidemiologia , Esquizofrenia/epidemiologia , Doenças Cardiovasculares/epidemiologia , Comorbidade , Doenças do Sistema Endócrino/epidemiologia , Métodos Epidemiológicos , Feminino , Humanos , Hepatopatias/epidemiologia , Pneumopatias/epidemiologia , Masculino , Pessoa de Meia-Idade , Neoplasias/epidemiologia , Transtornos Relacionados ao Uso de Substâncias/epidemiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA